ライフサイエンスコーパス: PET image

1 anners degrades the quantitative accuracy of PET image.

2 attenuation CT image and transferred to the PET image.

3 gistered to the single end-of-expiration NAC PET image.

4 om scans, cold artifacts were visible on the PET image.

5 ach other with no visual differences between PET images.

6 me-of-flight (TOF) and non-TOF reconstructed PET images.

7 TB SUVmean and SUVmax were assessed from the PET images.

8 awn over organs visible in the reconstructed PET images.

9 acquired 4D non-attenuation-corrected (NAC) PET images.

10 a feasible approach to motion correction of PET images.

11 cts the SUV measured for tumors in (18)F-FDG PET images.

12 o underwent amyloid PET and MRI, but not tau PET imaging.

13 ets while significantly reducing the cost of PET imaging.

14 tic resonance imaging but not tau or amyloid PET imaging.

15 uclide with a half-life of 12.7 h, ideal for PET imaging.

16 gate glucose utilization of BAT by (18)F-FDG PET imaging.

17 in healthy adult mice by dynamic and static PET imaging.

18 ikely to be achieved by the sole use of TSPO PET imaging.

19 p between fcMRI and both Tau-PET and amyloid-PET imaging.

20 vo radiography as well as static and dynamic PET imaging.

21 value was determined with the HEC method at PET imaging.

22 tivity MRI (fcMRI) in the context of amyloid-PET imaging.

23 racer for investigating tumor perfusion with PET imaging.

24 Bs)-were studied with whole-body (11)C-ER176 PET imaging.

25 well with the behavior observed by standard PET imaging.

26 h(Hor)-dAph(Cbm)-Lys-Thr-Cys)-dTyr-NH2)) for PET imaging.

27 tracer uptake was assessed by (18)F-AH113804 PET imaging.

28 s evaluated by (99m)Tc-MIBI SPECT /(18)F-FDG PET imaging.

29 ostic efficacy of beta-amyloid (Abeta) brain PET imaging.

30 8)F-FVIIai in the tumors measured in vivo by PET imaging.

31 2-deoxy-2-[F-18]fluoro-D-glucose ((18)F-FDG) PET imaging.

32 nt of NOD's elimination kinetics by means of PET imaging.

33 s synthesized to incorporate fluorine-18 for PET imaging.

34 ed the feasible application of (64)Cu(I) for PET imaging.

35 ghrelin receptor expressing carcinomas using PET imaging.

36 (68)Ga-DOTATOC (an sst receptor agonist), in PET imaging.

37 s-3 HABs, 3 MABs, and 2 LABs-underwent brain PET imaging.

38 ale, retired breeder Sprague-Dawley rats for PET imaging.

39 the in vivo status of DLL3 expression using PET imaging.

40 ng PDE4B-preferring radioligand for clinical PET imaging.

41 all cerebral emboli were detected in vivo by PET imaging.

42 se model of bleomycin-induced fibrosis using PET imaging.

43 d B (11C-PiB) positron emission tomographic (PET) imaging.

44 le for in vivo positron emission tomography (PET) imaging.

45 d non-invasive positron emission tomography (PET) imaging.

46 tory motion in positron emission tomography (PET) imaging.

47 (18)F-FDS were determined by dynamic 35-min PET imaging (15 frames x 8 s, 26 frames x 30 s, 20 frame

48 , in the tracer concentration range used for PET imaging, [(18)F]CFA is primarily a substrate for dCK

49 ge, 12.2 y; age range, 6.8-19.1 y) underwent PET imaging; 25 (74%) had localized disease.

50 Heterogeneity derived in vivo from PET images accurately reflects the heterogeneity of trac

51 recovery and uniformity were comparable for PET images acquired simultaneously with multiple MR cond

52 ifferences in the statistical quality of the PET images affected the textural parameters less than re

53 to determine the feasibility of the hypoxia PET imaging agent (64)Cu-ATSM to detect hypoxia in a rab

54 The new immuno-PET imaging agent (89)Zr-DFO-AMG102 was successfully syn

55 oss species of [(18) F]Nifene, a fast acting PET imaging agent for alpha4beta2* nAChRs.

56 A same-day PET imaging agent for measuring PD-L1 status in primary

57 usion:(64)Cu-DOTA-alendronate is a promising PET imaging agent for the sensitive and specific detecti

58 A CD3 PET imaging agent targeting T cells was synthesized to t

59 as modified for use as a (89)Zr-based immuno-PET imaging agent to noninvasively determine the local l

60 JR11 is under clinical development as a PET imaging agent when labeled with (68)Ga ((68)Ga-NODAG

61 te as a mammary microcalcification-targeting PET imaging agent, using an ideal rat model.

62 ose within the acceptable range for clinical PET imaging agents and the potential for translation int

63 Novel PET imaging agents for assessing vascular endothelial gr

64 ted for use as positron emission tomography (PET) imaging agents for prostate cancer.

65 Positron emission tomography (PET) imaging agents that detect amyloid plaques containi

66 PET imaging allowed for the sensitive detection of DIPG

67 Furthermore, PET imaging allows better quantification than the SPECT

68 Positron Emission Tomography (PET) imaging allows the estimation of multiple aspects o

69 rks learned from a clinical dataset of AV-45 PET image and compare network properties of both uncorre

70 64)Cu(I) and (64)Cu(II) was observed through PET images and biodistribution.

71 ugh followed in 2011 with (68)Ga-PSMA-11 for PET imaging and (131)I-MIP-1095 for endoradiotherapy of

72 -18 is the most widely used radioisotope for PET imaging and a thorough overview of the available rad

73 tter (P < 0.05-0.001) than (18)F-FDG through PET imaging and biodistribution studies in MDA-MB-231 an

74 PET imaging and biodistribution studies showed fast clea

75 ntly better than (18)F-FDG, as shown through PET imaging and biodistribution studies.

76 PET imaging and biodistribution were performed 24 h afte

77 ition and neuroinflammation, we used in vivo PET imaging and ex vivo autoradiography with Pittsburgh

78 In vivo PET imaging and ex vivo biodistribution studies were per

79 PET imaging and ex vivo biodistribution studies with (18

80 s a promising bimodal ligand for noninvasive PET imaging and intraoperative optical imaging of GRPr-e

81 macokinetics in human subjects using dynamic PET imaging and metabolite-corrected arterial input func

82 aging probe that can be used for noninvasive PET imaging and optical imaging of prostate cancer.

83 te that our mouse model permits longitudinal PET imaging and quantification of T-cell homing during i

84 escent-labeled (68)Ga-tilmanocept allows for PET imaging and real-time intraoperative detection of SL

85 n low-molecular-weight PSMA ligands for both PET imaging and therapeutic approaches, with a focus on

86 apy (PDT) with positron emission tomography (PET) imaging and internal radiotherapy (RT).

87 labeled version, (64)Cu-NOTA-PEG4-cRGD2, for PET imaging, and a fluorescent version, FITC-PEG4-cRGD2,

88 tau pathology, as measured with 18F-AV-1451-PET imaging, and cognitive deficits in Alzheimer's disea

89 eficient mice were used for biodistribution, PET imaging, and determination of in vivo metabolization

90 ND AND Amyloid-positron emission tomography (PET) imaging (API) detects amyloid-beta pathology early

91 PSMA PET imaging appears to outperform traditional imaging in

92 eneic DLBCL mouse model, this PARP1-targeted PET imaging approach allowed us to discriminate between

93 Our PARP1-targeted PET imaging approach may be an attractive addition to th

94 [18F]AV-1451) positron emission tomographic (PET) imaging are linked with clinical phenotype and cort

95 views the current evidence of ERalpha and PR PET imaging as predictive and early-response biomarkers

96 FTP and [(11)C]Pittsburgh compound B PET imaging as well as MRI were performed in seven patie

97 (18)F-FDG PET images at baseline and approximately 9 d after initi

98 -hydroxyephedrin ((11)C-HED) and (15)O-water PET imaging at rest and after exposure to mild cold (16

99 -hydroxyephedrin ((11)C-HED) and (15)O-water PET imaging at rest and after exposure to mild cold (16

100 Six texture indices derived from the PET images, autoradiographic images, and histologic imag

101 They all underwent [F-18]-AV-1451 PET imaging before death.

102 ed for biomarker development, with (18)F-FDG PET imaging being the most studied.

103 PET imaging, biodistribution, and dosimetry studies in m

104 PET imaging, biodistribution, autoradiography and immuno

105 There are several PET imaging biomarkers for Abeta including (11)C-PiB and

106 For PET imaging, both (68)Ga- and (18)F-labeled agents have

107 effective approach to expeditiously acquire PET images, but in this case, the pretargeting approach

108 Overall, our results suggest granzyme B PET imaging can serve as a quantitatively useful predict

109 Conclusion PET imaging characteristics associated with distant meta

110 In vivo PET imaging clearly visualized PD-L1 expression in mice

111 Furthermore, PET imaging confirmed that ccRCC tumors exhibited increa

112 e uptake of (18)F-FVIIai measured in vivo by PET imaging correlated (r = 0.72, P < 0.02) with TF prot

113 rection technique applied to gated (18)F-NaF PET images could enhance image quality and improve uptak

114 plied mathematical modeling to Abeta in vivo PET imaging data to investigate competing theories of Ab

115 alpha-(11)C-methyl-l-tryptophan ((11)C-AMT) PET imaging demonstrated increased tryptophan uptake and

116 PET imaging demonstrated rapid uptake of tracer in the P

117 Accurate quantification of uptake on PET images depends on accurate attenuation correction in

118 sonance imaging (MRI) experiments, Macroflor PET imaging detects changes in macrophage population siz

119 clinical trial was initiated to compare the PET imaging diagnostic potential of (18)F-4FMFES with th

120 Because of highly sensitive PET imaging even of tissues with low alphavbeta6 integri

121 PET imaging exhibited high kidney-to-blood contrast and

122 tumors were delineated semiautomatically on PET images, followed by the extraction of tumor-to-backg

123 ults confirm the feasibility of using 4D NAC PET images for accurate PET attenuation correction and r

124 ges in management resulting from PSMA ligand PET imaging for both biochemical recurrence and primary

125 spected Alzheimer disease) underwent dynamic PET imaging for up to 120 min after bolus injection of (

126 spected Alzheimer disease) underwent dynamic PET imaging for up to 120 min after bolus injection of (

127 sburgh compound B carbon 11-labeled PET (PiB-PET) imaging for Abeta.

128 451, T807) positron emission tomography (FTP-PET) imaging for tau and Pittsburgh compound B carbon 11

129 registration algorithm was used to align the PET images from 4 cardiac gates, preserving all counts,

130 vity distribution patterns and the (18)F-FDG PET images from 54 patients with breast cancer were used

131 e number of publications about PSMA-targeted PET imaging from 2013 to 2016 (e.g., a search of the Web

132 (89)Zr-MSB0010853 PET imaging gives insight into the in vivo behavior of M

133 For primary PC, PSMA ligand PET imaging has been shown to be superior to cross-secti

134 The current research-based evidence on PET imaging has demonstrated encouraging potential in th

135 ed that chelator-mediated nanoparticle-based PET imaging has its inherent drawbacks and can possibly

136 Hence, the increasing popularity of TSPO PET imaging has paradoxically introduced substantial unc

137 (68)Ga-labeled somatostatin receptor ligand PET imaging has recently been shown in preclinical and e

138 PET imaging has the potential to detect striatal molecul

139 nt of amyloid positron emission tomographic (PET) images has been approved by regulatory authorities

140 ose positron emission tomography ([(18)F]FDG-PET) imaging has an essential role in diagnosing DLBCL i

141 l and synthetic amino acids radiolabeled for PET imaging have been investigated in prostate cancer pa

142 ences in regional brain uptake of (64)Cu and PET image heterogeneity between the 2 groups of mice.

143 ratory and cardiac motion-compensated MR and PET images in less than 5 min.

144 Here we used PET imaging in 40 healthy adults to compare, within indi

145 ATATE PET imaging was compared to [(18)F]FDG PET imaging in 42 patients with atherosclerosis.

146 )Ga-NOTA-AE105 as a new radioligand for uPAR PET imaging in cancer patients.

147 )Ga-NOTA-AE105 as a new radioligand for uPAR PET imaging in cancer patients.

148 quent longitudinal change in Abeta using PIB-PET imaging in cognitively normal older adults.

149 PET imaging in non-human primates confirms that this rad

150 ed using ex vivo biodistribution and in vivo PET imaging in non-tumor-bearing animals as well as in K

151 ntal and neurodegenerative mouse models with PET imaging in patients with recent-onset schizophrenia

152 We tested the feasibility of (18)F-FDS renal PET imaging in rats.

153 ful tool to interrogate MYC via TfR-targeted PET imaging in TNBC.

154 n Alzheimer-related pathology by multitracer PET imaging in transgenic APPPS1-21 (TG) mice.

155 sed by (99m)Tc-duramycin SPECT and (18)F-FDG PET imaging in treatment-sensitive COLO205 and treatment

156 verview on the current status of PSMA ligand PET imaging, including imaging procedure and interpretat

157 ces to characterize tumor heterogeneity from PET images is being increasingly investigated in retrosp

158 Pseudotemporal analysis of baseline PET images is capable of predicting the regional pattern

159 clusion: Pseudotemporal analysis of baseline PET images is capable of predicting the regional pattern

160 FLAB-based segmentation on static (18)F-FDG PET images is in best agreement with pathology volume an

161 The current standard for breast PET imaging is (18)F-FDG.

162 he [18F]AV-1451 signal as seen on results of PET imaging is a valid marker of clinical symptoms and n

163 PET imaging is a widely applicable but a very expensive

164 Whether seizures also affect (18)F-FET PET imaging is currently unknown.

165 (18)F-FDG PET imaging is routinely used to investigate brown adipo

166 At present, (18)F-FDG PET imaging is the most widely used clinical tool for me

167 Amyloid positron emission tomography (PET) imaging is a valuable tool for research and diagnos

168 ocator-protein positron emission tomography (PET) imaging, is increased in unmedicated persons presen

169 The PET images matched ligand binding in post-mortem tissue,

170 ity ratios (T/B) obtained from [(18)F]4F-Gln PET images matched the distinct glutamine pool sizes of

171 We envision that SCN5A measurements using PET imaging may serve as a novel diagnostic tool to stra

172 formance more accurately than other fMRI and PET imaging measures.

173 Results Signal on PET images obtained in mouse lungs after injury with LPS

174 The contours were drawn on each PET image of each study.

175 Cs at the adventitia was evidenced by serial PET images of (89)Zr-labeled cells.

176 and quantitatively to measure the effect on PET images of iterative metal artifact reduction (iMAR)

177 eatures extracted from static and parametric PET images of non-small cell lung carcinoma (NSCLC) in o

178 adiation dose from whole-body (11)C-nicotine PET imaging of 11 healthy (5 male and 6 female) subjects

179 For PET imaging of 18-kDa translocator protein (TSPO), a bio

180 [18F]F-AraG PET imaging of a murine aGVHD model enabled visualizatio

181 PET imaging of amino acid transport using O-(2-(18)F-flu

182 Finally, small-animal PET imaging of an LNCaP tumor-bearing mouse was performe

183 e feasibility of a synthesis-free method for PET imaging of brown adipose tissue (BAT) and translocat

184 s changes in neural circuitry (measured with PET imaging of cerebral glucose metabolism at baseline a

185 is suitable for noninvasive, highly specific PET imaging of CXCR4 expression in the atherosclerotic a

186 Combining in vivo PET imaging of dopamine synthesis capacity, fMRI, and a

187 PET imaging of EAE and control mice was performed 1, 4,

188 LUT5 represents an alternative biomarker for PET imaging of hexose metabolism in BC.

189 ising candidate for preclinical and clinical PET imaging of hNIS expression and thyroid-related disea

190 re, we sought to optimize noninvasive immuno-PET imaging of human programmed death-ligand 1 (PD-L1) e

191 ble of standardizing quantitative changes in PET imaging of patients with metastatic prostate cancer

192 PET imaging of proliferation, angiogenesis, and DNA dama

193 PET imaging of tau pathology in Alzheimer disease may be

194 )F-DPA-714 is a second-generation tracer for PET imaging of the 18-kDa translocator protein (TSPO), a

195 c 4T1luc tumors, allowing for the successful PET imaging of the tumors as early as 2 h after injectio

196 f this study was to explore the potential of PET imaging of the urokinase-type plasminogen activator

197 F-GP1 is an (18)F-labeled small molecule for PET imaging of thrombi.

198 Hence, the time point for [(18)F]FLT-PET imaging of tumor response to gemcitabine is of cruci

199 ation of an antibody-based imaging agent for PET imaging of VEGFR-2 expression in vivo.

200 ting of TF for positron emission tomography (PET) imaging of pancreatic cancer.

201 e studies used positron emission tomography (PET) imaging of the TSPO microglial marker and found inc

202 Yet, tumor texture derived from PET images only coarsely reflects the spatial distributi

203 (68)Ga-PSMA HBED-CC PET imaging performed significantly superior to morpholo

204 Two PET images (PETA and PETB) were reconstructed using iden

205 (18)F-FDG PET images, postgadolinium MR images, and ADC MR images

206 C-radiolabeled sarcosine was tested as a new PET imaging probe in comparison with (11)C-choline in 2

207 We successfully developed 4-(11)C-MBZA as a PET imaging probe, displaying properties advantageous ov

208 We designed novel PET imaging probes for the murine and human granzyme B i

209 at early stages, and newer, more sensitive, PET imaging probes need to be developed.

210 tate-specific membrane antigen (PSMA)-ligand PET imaging provides unprecedented accuracy for whole-bo

211 c motion information was used to improve the PET image quality of a human in vivo scan.

212 Q.Clear reconstruction improves the PET image quality, with higher recovery coefficients and

213 formation that can be used to improve MR and PET image quality.

214 he impact of different heating conditions on PET imaging quantification was evaluated.

215 lective microglial markers are available for PET imaging, quantification of cytokines and other infla

216 hould be further studied to evaluate it as a PET imaging radiotracer.

217 Before undertaking (68)Ga-PSMA PET imaging, referring medical specialists completed a q

218 nflammation using (18)F-FAZA and (18)F-FMISO PET imaging represents a promising new tool for uncoveri

219 f this technique in myelofibrosis, (18)F-FLT PET imaging results were compared with bone marrow histo

220 r samples and correlated with (18)F-AH113804 PET imaging results.

221 he voxel-based analysis of the reconstructed PET images revealed quantification errors (aRC) of 13.2%

222 Rat small-animal PET images showed (11)C-metformin uptake in the kidney a

223 PET images showed optimal tumor visualization at 5-8 d a

224 In vivo PET imaging showed specific uptake in PSMA-expressing tu

225 We have developed a PET imaging strategy for DLBCL that targets poly[ADP rib

226 may be an attractive addition to the current PET imaging strategy to differentiate inflammation from

227 rotein expression levels in combination with PET imaging studies for functional characterization of G

228 as well as in vivo biodistribution and brain PET imaging studies in wildtype and mGluR2 knockout rats

229 In subsequent non-human primate (NHP) PET imaging studies, [(18)F]8 showed rapid brain uptake

230 nifest and premanifest HDGECs as measured by PET imaging studies.

231 he past years, positron emission tomography (PET) imaging studies have investigated striatal molecula

232 F-Mefway) for positron emission tomography (PET) imaging studies of serotonin 5-HT1A receptors which

233 estigations indicated that the presence of a PET imaging study demonstrating abnormalities in individ

234 By combining data from a PET imaging study using (89)Zr-labeled bevacizumab and a

235 of the potential of combining a multitracer PET imaging technique and a longitudinal protocol applie

236 cterize a specific small-molecule tracer for PET imaging that binds with high affinity to GPIIb/IIIa

237 On small-animal PET images, the tumor was clearly delineated soon after

238 ents were examined using [(11) C]PBR28 brain PET imaging to assess brain immune cell activation.

239 view should be below 3.3 GBq at the time of PET imaging to avoid deadtime losses for this scanner.

240 monstrate the utility of noninvasive in vivo PET imaging to dynamically track T-cell checkpoint recep

241 We used (11)C-metoclopramide PET imaging to elucidate the kinetic impact of transport

242 nducted a first-in-human study of (18)F-MFBG PET imaging to evaluate the safety, feasibility, pharmac

243 11-labeled Pittsburgh Compound B ([11C]PiB) PET imaging to measure amyloid burden, and structural ma

244 Patients underwent [18F]AV-1451 PET imaging to measure tau burden, carbon 11-labeled Pit

245 In this study, we used PET imaging to study the pharmacokinetics and tumor deli

246 oxyglucose positron emission tomography (FDG-PET) imaging to determine the utility of response-adapte

247 oxyglucose positron emission tomography (FDG-PET) imaging to understand the neural systems governing

248 of approximately 10 nm, as measured by using PET imaging tracing.

249 linical profiles, structural MRI and amyloid PET imaging typical for svPPA, FTP signal was unexpected

250 Dynamic PET imaging under baseline and blocking conditions deter

251 Conclusion: Dynamic PET imaging under baseline and blocking conditions deter

252 nce (MR), and positron emission tomographic (PET) image uniformity and noise by using uniform phantom

253 can be clearly visualized using small-animal PET imaging up to 72 h after injection.

254 c accumulation in TF-positive BXPC-3 tumors, PET imaging using (89)Zr-Df-ALT-836 promises to open new

255 In this study, uPAR PET imaging using a (68)Ga-labeled version of the uPAR-t

256 PET imaging using aged, female, retired breeder rats sho

257 coma, or cancer of unknown primary underwent PET imaging using the novel CXCR4 nuclear probe (68)Ga-p

258 Human PET imaging using the second-generation TSPO radiotracer

259 ne ((18)F-FLT) is a proliferation tracer for PET imaging valuable in the monitoring of disease progre

260 In vivo PET imaging visualized rapid excretion of the administra

261 TPM mouse model, suggesting that (64)Cu-GTSM PET imaging warrants clinical evaluation as a diagnostic

262 Quantitative assessment of PET images was performed by volume-of-interest and ratio

263 (68)Ga-DOTATATE PET imaging was compared to [(18)F]FDG PET imaging in 42

264 PET imaging was performed for (68)Ga-aquibeprin and the

265 (18)F-AV-1451 PET imaging was performed on 43 subjects (5 young HCs, 2

266 Dosimetry from multi-time-point PET imaging was performed with OLINDA/EXM.

267 tly after administration of 3 MBq/kg of FCH, PET imaging was performed, followed by T1- and T2-weight

268 Dynamic whole-body PET imaging was used to determine the insulin-mediated (

269 PET imaging was used to evaluate the whole-body distribu

270 Here, using PET imaging, we investigated whether lung cancer PDXs re

271 Both static and parametric PET images were analyzed, with quantitative parameters (

272 The reconstructed PET images were compared with those obtained using the r

273 With use of TOF PET data, PET images were reconstructed with four different attenu

274 Baseline non-TOF and TOF PET images were reconstructed.

275 Static PET images were recorded immediately after MRI acquisiti

276 All reconstructed 4D NAC PET images were then elastically registered to the singl

277 PET images were visually analyzed for visible tumor upta

278 rment n = 116) with standardized MRI and PiB-PET imaging were included.

279 In vivo biodistribution and small-animal PET imaging were performed in mice bearing B16F1 melanom

280 Dynamic positron emission tomography (PET) images were acquired post-injection of free (18)F-F

281 abolic tumor phenotypes that are captured in PET images, whereas KRAS-mutated tumors do not.

282 abolic tumor phenotypes that are captured in PET images, whereas KRAS-mutated tumors do not.

283 particle-based positron emission tomography (PET) imaging, whereas its accuracy remains questionable.

284 PET imaging, whole-body probe counts, and blood draws we

285 erphosphorylated tau in vivo, results of tau PET imaging will likely serve as a key biomarker that li

286 When evaluating (18)F-FDG PET images with the Deauville score (DS), the quantifica

287 PET imaging with (18)F-DCFBC, a small-molecule PSMA-targ

288 pathology were obtained through small-animal PET imaging with (18)F-FDG, (18)F-peripheral benzodiazep

289 PET imaging with (18)F-MFBG allows for same-day imaging

290 tly published biodistribution data of immuno-PET imaging with (64)Cu-cetuximab and of small-animal SP

291 Longitudinal PET imaging with (64)Cu-NOTA-FVIIai showed a tumor uptak

292 Using PET imaging with a radiotracer specific for the serotoni

293 disease; it is the first example of in vivo PET imaging with a tracer containing an S-(18)F bond.

294 Longitudinal quantitative small-animal PET imaging with an arterial input function can be perfo

295 a first look at the relationship between Tau-PET imaging with F(18)-AV1451 and functional connectivit

296 rther validation in large samples, (18)F-FDG PET imaging with network analysis may provide a viable b

297 c resonance-positron emission tomography (MR-PET) imaging with (11) C-PBR28, we quantified expression

298 re we describe positron emission tomography (PET) imaging with (18)F-Macroflor, a modified polyglucos

299 Positron emission tomography (PET) imaging with radiotracers that target translocator

300 = 3), we used positron emission tomography (PET) imaging with the radioligand [(11)C]AZ10419369 admi